PP
OREX

Paloma Partners’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Paloma Partners’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-7,550
Closed -$374K – 2291
2015
Q2 		$374K Buy
+7,550
New +$451K 0.01% 1223

Other funds holding OREX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's OREX Position: Q3 2015 in Review

Paloma Partners sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 7,550 shares — an estimated $374K sold.

Paloma Partners first reported a position in OREX in Q2 2015 and held it in 1 quarter. The position peaked at $374K in Q2 2015. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

  • Paloma Partners reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Paloma Partners sold 7,550 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $374K.
  • Paloma Partners first reported a position in Orexigen Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Paloma Partners's Orexigen Therapeutics, Inc. position peaked at $374K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Paloma Partners's 13F filing for Q3 2015, filed 16 Nov 2015.